Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2: A phase 1 randomized clinical trial

BACKGROUND: We used the RNActive® technology platform (CureVac N.V., Tübingen, Germany) to prepare CVnCoV, a COVID-19 vaccine containing sequence-optimized mRNA coding for a stabilized form of SARS-CoV‑2 spike (S) protein encapsulated in lipid nanoparticles (LNP). METHODS: This is an interim analysi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kremsner, Peter G., Mann, Philipp, Kroidl, Arne, Leroux-Roels, Isabel, Schindler, Christoph, Gabor, Julian J., Schunk, Mirjam, Leroux-Roels, Geert, Bosch, Jacobus J., Fendel, Rolf, Kreidenweiss, Andrea, Velavan, Thirumalaisamy P., Fotin-Mleczek, Mariola, Mueller, Stefan O., Quintini, Gianluca, Schönborn‑Kellenberger, Oliver, Vahrenhorst, Dominik, Verstraeten, Thomas, Alves de Mesquita, Margarida, Walz, Lisa, Wolz, Olaf‑Oliver, Oostvogels, Lidia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8354521/
https://www.ncbi.nlm.nih.gov/pubmed/34378087
http://dx.doi.org/10.1007/s00508-021-01922-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8354521/
https://www.ncbi.nlm.nih.gov/pubmed/34378087
http://dx.doi.org/10.1007/s00508-021-01922-y

Ejemplares similares